What it does
The reference panels
To diagnose. The only test that confirms lymphoma. A core or excisional biopsy is needed; a fine-needle sample is usually too small to name the subtype.
On the biopsy. Stains for proteins such as CD20 and CD30 that identify the subtype and the targets drugs can attack.
On the biopsy, blood or marrow. Reads surface markers on thousands of cells to show a single abnormal clone.
Aggressive B-cell lymphoma. Finds rearrangements of MYC, BCL2 and BCL6, which can change the treatment chosen.
Selected subtypes. Mutations that refine the diagnosis or point to a targeted drug.
At diagnosis and before every cycle. Shows whether the marrow is involved and whether counts are safe for the next dose.
At diagnosis and during treatment. Kidney and liver function, which decide drug doses.
At diagnosis. Rises with tumor burden, and is part of the IPI risk score.
Before the first cycle. Flags the risk of tumor lysis syndrome when treatment starts.
Some subtypes. A risk marker in follicular lymphoma and CLL/SLL.
Hodgkin lymphoma. Part of the risk assessment for early-stage Hodgkin lymphoma.
Before rituximab or similar drugs. These drugs can reactivate hidden hepatitis B. A positive result usually means preventive antiviral medicine.
Before treatment. Linked to some lymphomas; treating the virus can matter for the lymphoma too.
Before treatment. Changes the treatment plan and the infections to guard against.
Staging, and after treatment. Shows where the lymphoma is and, afterwards, whether any remains active (the Deauville score).
When PET-CT does not settle it. Checks the marrow. Often skipped in Hodgkin lymphoma and DLBCL when PET-CT answers the question.
Before anthracyclines. Measures heart function before drugs such as doxorubicin, which can weaken it.
Before bleomycin. Bleomycin can scar the lungs; a baseline makes any change visible.
Before treatment. Chemotherapy and radiotherapy can harm a pregnancy. Fertility preservation is discussed at the same time.
When the risk to the brain and spine is high. Checks spinal fluid in the subtypes and stages that can spread there.
CLL/SLL, and after rituximab. Low antibody levels raise infection risk and can be replaced.
At diagnosis. Deficiency is common and easy to correct. Low levels are linked with worse outcomes in studies, though cause and effect are unproven.
At the first visit. A magnified scalp exam that tells pattern loss, alopecia areata and scarring apart.
At the first visit. Shows whether shedding is active, and where.
Diffuse shedding. Finds anemia, a common and treatable contributor.
Diffuse shedding. Measures iron stores. Low ferritin is linked to shedding even without anemia.
If ferritin is low or unclear. Ferritin rises with inflammation and can hide a deficiency; serum iron and transferrin saturation settle it.
Diffuse shedding or patches. An under- or overactive thyroid causes diffuse loss, and thyroid disease is linked with alopecia areata.
Shedding or alopecia areata. Low levels are common in both, and a deficiency is simple to correct.
If diet or absorption suggests a deficiency. Deficiency causes hair loss. Supplementing without one does not help.
Vegan diets or gut disease. Deficiency is more likely in both and is linked with diffuse shedding.
Women with signs of excess androgens. Irregular periods, acne or excess hair alongside thinning point to hormones.
Signs of excess androgens. An adrenal androgen; a very high level needs further investigation.
Irregular periods. A raised level disturbs other hormones and can contribute to thinning.
If lupus is suspected. Lupus can cause both scarring and non-scarring hair loss.
Patchy, moth-eaten loss. Secondary syphilis causes a patchy pattern that antibiotics cure.
Scarring, or an unclear pattern. Confirms scarring alopecia, where early treatment preserves follicles.
Scaly patches, mostly in children. Diagnoses tinea capitis, which needs antifungal tablets.
Every visit. Sets the level of treatment, and shows whether it is working.
Every year. Five questions that screen for psoriatic arthritis, which can cause lasting joint damage if missed.
If joints are painful. Help tell psoriatic arthritis from rheumatoid arthritis.
If joints are painful. Markers of inflammation that support an arthritis diagnosis.
If arthritis is suspected. Shows inflammation and erosions in the joints.
At diagnosis, then periodically. Psoriasis raises the risk of heart disease; cholesterol is part of measuring it.
At diagnosis, then periodically. Screens for diabetes, which is more common with psoriasis.
Every visit. Part of metabolic screening, and monitored closely on cyclosporine.
Before and during systemic treatment. Fatty liver is more common with psoriasis, and methotrexate is processed by the liver.
Before methotrexate or cyclosporine. Methotrexate is cleared by the kidneys and cyclosporine can harm them.
Before and during systemic treatment. Methotrexate can lower blood counts.
Before biologics and some tablets. These drugs can reactivate latent tuberculosis. A positive test means preventive treatment first.
Before systemic treatment. Several treatments can worsen hidden viral hepatitis.
Before systemic treatment. Affects which treatments are safe.
Before methotrexate or acitretin. Both can harm a pregnancy; after acitretin, pregnancy must be avoided for three years.
Sudden guttate psoriasis. A strep throat often triggers guttate psoriasis.
If the diagnosis is unclear. Separates psoriasis from eczema, fungal infection and rarer conditions.
Every year. Depression is more common with psoriasis and worth asking about directly.
Every visit. Shows whether a treatment is working after eight to twelve weeks.
Signs of excess androgens. Irregular periods, excess hair or sudden adult acne suggest a hormonal cause.
Signs of excess androgens. An adrenal androgen; a very high level needs further investigation.
Suspected polycystic ovary syndrome. Help separate polycystic ovary syndrome from other causes of irregular cycles.
Signs of excess androgens. Screens for non-classic congenital adrenal hyperplasia, which mimics polycystic ovary syndrome.
Irregular periods. Rules out raised prolactin as the cause of cycle changes.
Suspected polycystic ovary syndrome. Insulin resistance is common in the syndrome and worth finding early.
Before and during isotretinoin. Isotretinoin causes severe birth defects; testing is required before and during treatment.
Before and during isotretinoin. Isotretinoin can raise triglycerides.
Before and during isotretinoin. Checks for the occasional rise in liver enzymes.
Spironolactone, with risk factors. Rarely needed in healthy young women; checked with kidney disease or interacting drugs.
Acne that worsens on antibiotics. Finds gram-negative folliculitis, which needs different treatment.
At diagnosis and follow-up. Ultraviolet light shows faint patches and how far the disease extends.
At diagnosis, then every few months. A baseline, so spread or repigmentation is measured rather than guessed.
At diagnosis, then periodically. Thyroid disease is markedly more common with vitiligo.
At diagnosis. Signal thyroid disease risk before TSH changes.
At diagnosis. A baseline, and a check for anemia.
If anemia or symptoms suggest it. Pernicious anemia, an autoimmune cause of low B12, occurs more often with vitiligo.
Symptoms of diabetes. Type 1 diabetes is among the autoimmune conditions linked to vitiligo.
With strict sun protection, or before phototherapy. Sun avoidance lowers vitamin D, and a deficiency is easy to correct.
Before phototherapy, if sun-sensitive. Screens for lupus and other conditions that light can worsen.
If the diagnosis is unclear. Separates vitiligo from other causes of pale patches.
Only with symptoms. Addison's disease is rare but linked; fatigue, weight loss and low blood pressure warrant the test.
The rest of it
Five conditions, from the first test to long-term care
Something to use, not only something to read
Drafts the plan. Your doctor decides.
Symptoms, photos, results and scores, over time
Retests, treatments and appointments, on one schedule
Support from people living with the same condition